Pancreatic cancer is a particularly tough opponent among cancers, and one type that stands out in its aggression is pancreatic ductal adenocarcinoma (PDAC).
This type of cancer grows and spreads so quickly that most patients face grim statistics, with only about 8% surviving more than five years after diagnosis.
In a world where effective treatments for PDAC are sorely lacking, a spark of hope has emerged from recent research at the Francis Crick Institute.
A team of scientists led by Axel Behrens has uncovered new insights that could pave the way for better treatment options.
Their findings, detailed in the journal Nature Cell Biology, shed light on a specific aspect of the cancer’s biology that could be key to curbing its growth.
At the heart of their research are cancer stem cells, which play a pivotal role in both the initiation and progression of tumors.
Similar to the stem cells found in healthy tissues that help repair and regenerate our organs, cancer stem cells have the ability to start new tumors and morph into various types of tumor cells. This makes them particularly formidable, as they contribute to the cancer spreading and becoming more difficult to treat.
During their investigation, the researchers focused on analyzing the genes expressed in these stem cells and discovered a protein called CD9, which appears on the surface of these cells.
They noticed that CD9 was present not just in advanced tumors, but also in those just beginning to form. This was a significant discovery because it suggested that CD9 could serve as a marker to identify these aggressive cancer stem cells early in the tumor’s development.
However, the role of CD9 extends beyond just marking these cells. The researchers found that this protein also influences how malignant the cancer stem cells are.
By experimenting with the levels of CD9 in the cancer cells of mice, they observed that reducing CD9 led to smaller tumors, whereas increasing it caused the cells to become more aggressive, resulting in larger and quickly forming tumors.
Further analysis revealed an even more direct connection between CD9 and the severity of the cancer.
Data from existing clinical studies showed that patients whose tumor cells had high levels of CD9 had a poorer prognosis, with about 10% of PDAC patients showing elevated levels of this protein.
To unravel how CD9 contributes to cancer growth, the scientists looked at how cancer stem cells metabolize nutrients.
They discovered that CD9 enhances the cells’ intake of glutamine, a nutrient that fuels the rapid growth of cancer. By boosting glutamine uptake, CD9 essentially feeds the cancer, helping it grow and spread.
This breakthrough provides a new angle of attack in the fight against pancreatic cancer. By targeting the CD9 protein, future treatments could potentially inhibit the uptake of glutamine by the cancer cells, effectively starving the cancer and halting its growth.
Such strategies could not only extend the lives of those diagnosed with this deadly disease but also improve their quality of life, offering a ray of hope where there was previously very little.
As research progresses, the possibility of turning these findings into real-world treatments offers a glimpse of a future where pancreatic cancer could be much more manageable or even curable.
It’s a testament to the relentless pursuit of science to find new ways to fight one of the most challenging diseases known to humanity.
If you care about cancer risk, please read studies that exercise may stop cancer in its tracks, and vitamin D can cut cancer death risk.
For more information about cancer, please see recent studies that yogurt and high-fiber diet may cut lung cancer risk, and results showing that new cancer treatment may reawaken the immune system.
Follow us on Twitter for more articles about this topic.
Copyright © 2024 Scientific Diet. All rights reserved.
